These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23060796)

  • 1. Ouabain Mimics Low Temperature Rescue of F508del-CFTR in Cystic Fibrosis Epithelial Cells.
    Zhang D; Ciciriello F; Anjos SM; Carissimo A; Liao J; Carlile GW; Balghi H; Robert R; Luini A; Hanrahan JW; Thomas DY
    Front Pharmacol; 2012; 3():176. PubMed ID: 23060796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant.
    Yu W; Kim Chiaw P; Bear CE
    J Biol Chem; 2011 Jul; 286(28):24714-25. PubMed ID: 21602569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells.
    Favia M; Mancini MT; Bezzerri V; Guerra L; Laselva O; Abbattiscianni AC; Debellis L; Reshkin SJ; Gambari R; Cabrini G; Casavola V
    Am J Physiol Lung Cell Mol Physiol; 2014 Jul; 307(1):L48-61. PubMed ID: 24816489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
    Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect.
    Robert R; Carlile GW; Pavel C; Liu N; Anjos SM; Liao J; Luo Y; Zhang D; Thomas DY; Hanrahan JW
    Mol Pharmacol; 2008 Feb; 73(2):478-89. PubMed ID: 17975008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of Cystic Fibrosis Transmembrane Conductance Regulator Function in Human Bronchial Epithelial Cells via SLC6A14-Dependent Amino Acid Uptake. Implications for Treatment of Cystic Fibrosis.
    Ahmadi S; Wu YS; Li M; Ip W; Lloyd-Kuzik A; Di Paola M; Du K; Xia S; Lew A; Bozoky Z; Forman-Kay J; Bear CE; Gonska T
    Am J Respir Cell Mol Biol; 2019 Dec; 61(6):755-764. PubMed ID: 31189070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR.
    Sampson HM; Robert R; Liao J; Matthes E; Carlile GW; Hanrahan JW; Thomas DY
    Chem Biol; 2011 Feb; 18(2):231-42. PubMed ID: 21338920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue of functional F508del cystic fibrosis transmembrane conductance regulator by vasoactive intestinal peptide in the human nasal epithelial cell line JME/CF15.
    Rafferty S; Alcolado N; Norez C; Chappe F; Pelzer S; Becq F; Chappe V
    J Pharmacol Exp Ther; 2009 Oct; 331(1):2-13. PubMed ID: 19584307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
    Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
    J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Searching for combinations of small-molecule correctors to restore f508del-cystic fibrosis transmembrane conductance regulator function and processing.
    Boinot C; Jollivet Souchet M; Ferru-Clément R; Becq F
    J Pharmacol Exp Ther; 2014 Sep; 350(3):624-34. PubMed ID: 24970923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.
    Hanrahan JW; Sato Y; Carlile GW; Jansen G; Young JC; Thomas DY
    Expert Opin Ther Targets; 2019 Aug; 23(8):711-724. PubMed ID: 31169041
    [No Abstract]   [Full Text] [Related]  

  • 13. Compounds that correct F508del-CFTR trafficking can also correct other protein trafficking diseases: an in vitro study using cell lines.
    Sampson HM; Lam H; Chen PC; Zhang D; Mottillo C; Mirza M; Qasim K; Shrier A; Shyng SL; Hanrahan JW; Thomas DY
    Orphanet J Rare Dis; 2013 Jan; 8():11. PubMed ID: 23316740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
    Chung WJ; Goeckeler-Fried JL; Havasi V; Chiang A; Rowe SM; Plyler ZE; Hong JS; Mazur M; Piazza GA; Keeton AB; White EL; Rasmussen L; Weissman AM; Denny RA; Brodsky JL; Sorscher EJ
    PLoS One; 2016; 11(10):e0163615. PubMed ID: 27732613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.
    Van Goor F; Hadida S; Grootenhuis PD; Burton B; Stack JH; Straley KS; Decker CJ; Miller M; McCartney J; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu PA
    Proc Natl Acad Sci U S A; 2011 Nov; 108(46):18843-8. PubMed ID: 21976485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR.
    Bose SJ; Bijvelds MJC; Wang Y; Liu J; Cai Z; Bot AGM; de Jonge HR; Sheppard DN
    Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L71-L86. PubMed ID: 30969810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-16 rescues F508del-CFTR function in native cystic fibrosis epithelial cells.
    Kumar P; Bhattacharyya S; Peters KW; Glover ML; Sen A; Cox RT; Kundu S; Caohuy H; Frizzell RA; Pollard HB; Biswas R
    Gene Ther; 2015 Nov; 22(11):908-16. PubMed ID: 26133785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule.
    Liu J; Bihler H; Farinha CM; Awatade NT; Romão AM; Mercadante D; Cheng Y; Musisi I; Jantarajit W; Wang Y; Cai Z; Amaral MD; Mense M; Sheppard DN
    Br J Pharmacol; 2018 Apr; 175(7):1017-1038. PubMed ID: 29318594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latonduine Analogs Restore F508del-Cystic Fibrosis Transmembrane Conductance Regulator Trafficking through the Modulation of Poly-ADP Ribose Polymerase 3 and Poly-ADP Ribose Polymerase 16 Activity.
    Carlile GW; Robert R; Matthes E; Yang Q; Solari R; Hatley R; Edge CM; Hanrahan JW; Andersen R; Thomas DY; Birault V
    Mol Pharmacol; 2016 Aug; 90(2):65-79. PubMed ID: 27193581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.